These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37664314)

  • 1. Gender Disparities in Prolactinomas: Unravelling Clinical Patterns, Metabolic Variations, and Treatment Responses.
    Baba MS; Islam Mir SU; Bhat MH; Laway BA; Misgar RA
    Cureus; 2023 Aug; 15(8):e42911. PubMed ID: 37664314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Abnormalities, Inflammatory Markers and Endothelial Dysfunction in Hyperprolactinemia due to Prolactinoma before and after Normalization of Serum Prolactin: A Prospective Case Control Study.
    Baba MS; Laway BA; Misgar RA; Wani AI; Bashir MI; Bhat IA; Haq MG; Shah ZA
    Indian J Endocrinol Metab; 2023; 27(4):357-364. PubMed ID: 37867992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
    Schwetz V; Librizzi R; Trummer C; Theiler G; Stiegler C; Pieber TR; Obermayer-Pietsch B; Pilz S
    Metab Brain Dis; 2017 Feb; 32(1):155-161. PubMed ID: 27525431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline.
    Pala NA; Laway BA; Misgar RA; Dar RA
    Diabetol Metab Syndr; 2015; 7():99. PubMed ID: 26583049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
    Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
    Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study.
    Posawetz AS; Trummer C; Pandis M; Aberer F; Pieber TR; Obermayer-Pietsch B; Pilz S; Theiler-Schwetz V
    BMC Endocr Disord; 2021 Apr; 21(1):81. PubMed ID: 33902531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The gender features of disorders of composition of lipids of blood serum in patients with chronic pathology of kidneys.].
    Murkamilov IT; Aytabaiev KA; Fomin VV; Murkamilova ZA; Rayimjanov ZR; Redjapova NA; Yusupov FA; Aydarov ZA
    Klin Lab Diagn; 2018; 63(3):152-158. PubMed ID: 30673194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study.
    Portari LHC; Correa-Silva SR; Abucham J
    Neuroendocrinology; 2022; 112(1):68-73. PubMed ID: 33477154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
    Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
    Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Women with prolactinomas presented at the postmenopausal period.
    Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects of dopamine-agonists treatment among patients with prolactinomas.
    Kabootari M; Shirmohammadli H; Golgiri F; Mosalamiaghili S; Khajavi A; Akbari H
    Endocrine; 2023 Mar; 79(3):537-544. PubMed ID: 36352337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
    Pirchio R; Auriemma RS; Solari D; Arnesi M; Pivonello C; Negri M; de Angelis C; Cavallo LM; Cappabianca P; Colao A; Pivonello R
    Front Endocrinol (Lausanne); 2021; 12():769744. PubMed ID: 34917030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
    dos Santos Silva CM; Barbosa FR; Lima GA; Warszawski L; Fontes R; Domingues RC; Gadelha MR
    Obesity (Silver Spring); 2011 Apr; 19(4):800-5. PubMed ID: 20559294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.
    Berinder K; Nyström T; Höybye C; Hall K; Hulting AL
    Pituitary; 2011 Sep; 14(3):199-207. PubMed ID: 21128120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management.
    Pekić S; Medic Stojanoska M; Popovic V
    Neuroendocrinology; 2019; 109(1):28-33. PubMed ID: 30347396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?
    Perić B; Kruljac I; Šundalić S; Pećina HI; Jović A; Štefanović M; Butorac D; Vrkljan M
    Endocr Res; 2016 Aug; 41(3):200-6. PubMed ID: 26864960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
    Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
    Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.